IDiyas

For the Inventor, By the Inventor

The patent badge is an abbreviated version of the USPTO patent document. The patent badge does contain a link to the full patent document.

The patent badge is an abbreviated version of the USPTO patent document. The patent badge covers the following: Patent number, Date patent was issued, Date patent was filed, Title of the patent, Applicant, Inventor, Assignee, Attorney firm, Primary examiner, Assistant examiner, CPCs, and Abstract. The patent badge does contain a link to the full patent document (in Adobe Acrobat format, aka pdf). To download or print any patent click here.

Patent No.:

US 11407712 B1

PDFFull Text
Date of Patent:
Aug. 09, 2022

Filed:

Mar. 18, 2021

Tetralin and tetrahydroquinoline compounds as inhibitors of hif-2α

Applicant:

Arcus Biosciences, Inc., Hayward, CA (US);

Inventors:

Joel Worley Beatty, San Mateo, CA (US);

Samuel Lawrie Drew, Millbrae, CA (US);

Matthew Epplin, South San Francisco, CA (US);

Jeremy Thomas Andre Fournier, Fremont, CA (US);

Balint Gal, Hayward, CA (US);

Tezcan Guney, Hayward, CA (US);

Karl T. Haelsig, Berkeley, CA (US);

Clayton Hardman, San Francisco, CA (US);

Steven Donald Jacob, Oakland, CA (US);

Jenna Leigh Jeffrey, Oakland, CA (US);

Jaroslaw Kalisiak, Mountain View, CA (US);

Kenneth Victor Lawson, San Francisco, CA (US);

Manmohan Reddy Leleti, Dublin, CA (US);

Erick Allen Lindsey, San Diego, CA (US);

Artur Karenovich Mailyan, Hayward, CA (US);

Debashis Mandal, Fremont, CA (US);

Guillaume Mata, Berkeley, CA (US);

Hyunyoung Moon, Foster City, CA (US);

Jay Patrick Powers, Pacifica, CA (US);

Brandon Reid Rosen, San Mateo, CA (US);

Yongli Su, Foster City, CA (US);

Anh Thu Tran, Union City, CA (US);

Zhang Wang, Petaluma, CA (US);

Xuelei Yan, Foster City, CA (US);

Kai Yu, Hayward, CA (US);

Assignee:

ARCUS BIOSCIENCES, INC., Hayward, CA (US);

Attorney:

Mintz Levin Cohn Ferris Glovsky and Popeo PC

Primary Examiner:

Golam M Shameem

Int. Cl.
CPC ...
C07C 317/32 (2006.01); A61K 31/10 (2006.01); A61K 31/277 (2006.01); A61K 31/343 (2006.01); A61K 31/353 (2006.01); A61K 31/365 (2006.01); A61K 31/381 (2006.01); A61K 31/404 (2006.01); A61K 31/415 (2006.01); A61K 31/416 (2006.01); A61K 31/4174 (2006.01); A61K 31/4192 (2006.01); A61K 31/4196 (2006.01); A61K 31/421 (2006.01); A61K 31/423 (2006.01); A61K 31/426 (2006.01); A61K 31/428 (2006.01); A61K 31/437 (2006.01); A61K 31/44 (2006.01); A61K 31/4412 (2006.01); A61K 31/47 (2006.01); A61K 31/4709 (2006.01); A61K 31/472 (2006.01); A61K 31/4965 (2006.01); A61K 31/50 (2006.01); A61K 31/5025 (2006.01); A61K 31/505 (2006.01); A61K 31/519 (2006.01); A61K 31/538 (2006.01); A61K 39/395 (2006.01); A61K 45/06 (2006.01); C07C 255/53 (2006.01); C07C 317/22 (2006.01); C07C 317/36 (2006.01); C07D 209/34 (2006.01); C07D 211/86 (2006.01); C07D 213/57 (2006.01); C07D 213/71 (2006.01); C07D 213/73 (2006.01); C07D 213/74 (2006.01); C07D 213/84 (2006.01); C07D 215/48 (2006.01); C07D 217/04 (2006.01); C07D 231/12 (2006.01); C07D 231/56 (2006.01); C07D 233/64 (2006.01); C07D 237/20 (2006.01); C07D 239/42 (2006.01); C07D 241/12 (2006.01); C07D 249/06 (2006.01); C07D 249/08 (2006.01); C07D 263/32 (2006.01); C07D 263/57 (2006.01); C07D 265/36 (2006.01); C07D 277/30 (2006.01); C07D 277/56 (2006.01); C07D 277/64 (2006.01); C07D 307/83 (2006.01); C07D 311/22 (2006.01); C07D 333/64 (2006.01); C07D 401/04 (2006.01); C07D 401/10 (2006.01); C07D 409/10 (2006.01); C07D 413/10 (2006.01); C07D 471/04 (2006.01); C07D 487/04 (2006.01);
U.S. Cl.
CPC ...
C07C 317/32 (2013.01); A61K 31/10 (2013.01); A61K 31/277 (2013.01); A61K 31/343 (2013.01); A61K 31/353 (2013.01); A61K 31/365 (2013.01); A61K 31/381 (2013.01); A61K 31/404 (2013.01); A61K 31/415 (2013.01); A61K 31/416 (2013.01); A61K 31/4174 (2013.01); A61K 31/4192 (2013.01); A61K 31/4196 (2013.01); A61K 31/421 (2013.01); A61K 31/423 (2013.01); A61K 31/426 (2013.01); A61K 31/428 (2013.01); A61K 31/437 (2013.01); A61K 31/44 (2013.01); A61K 31/4412 (2013.01); A61K 31/47 (2013.01); A61K 31/472 (2013.01); A61K 31/4709 (2013.01); A61K 31/4965 (2013.01); A61K 31/50 (2013.01); A61K 31/505 (2013.01); A61K 31/5025 (2013.01); A61K 31/519 (2013.01); A61K 31/538 (2013.01); A61K 39/3955 (2013.01); A61K 45/06 (2013.01); C07C 255/53 (2013.01); C07C 317/22 (2013.01); C07C 317/36 (2013.01); C07D 209/34 (2013.01); C07D 211/86 (2013.01); C07D 213/57 (2013.01); C07D 213/71 (2013.01); C07D 213/73 (2013.01); C07D 213/74 (2013.01); C07D 213/84 (2013.01); C07D 215/48 (2013.01); C07D 217/04 (2013.01); C07D 231/12 (2013.01); C07D 231/56 (2013.01); C07D 233/64 (2013.01); C07D 237/20 (2013.01); C07D 239/42 (2013.01); C07D 241/12 (2013.01); C07D 249/06 (2013.01); C07D 249/08 (2013.01); C07D 263/32 (2013.01); C07D 263/57 (2013.01); C07D 265/36 (2013.01); C07D 277/30 (2013.01); C07D 277/56 (2013.01); C07D 277/64 (2013.01); C07D 307/83 (2013.01); C07D 311/22 (2013.01); C07D 333/64 (2013.01); C07D 401/04 (2013.01); C07D 401/10 (2013.01); C07D 409/10 (2013.01); C07D 413/10 (2013.01); C07D 471/04 (2013.01); C07D 487/04 (2013.01); C07C 2602/08 (2017.05); C07C 2602/10 (2017.05);
Abstract

Compounds that inhibit HIF-2α, and compositions containing the compound(s) and methods for synthesizing the compounds, are described herein. Also described are the use of such compounds and compositions for the treatment of a diverse array of diseases, disorders, and conditions, including cancer- and immune-related disorders that are mediated, at least in part, by HIF-2α.

Find Patent Forward Citations

Loading…